Annual Cash & Cash Equivalents
$114.89 M
-$116.84 M-50.42%
31 December 2023
Summary:
Iovance Biotherapeutics annual cash & cash equivalents is currently $114.89 million, with the most recent change of -$116.84 million (-50.42%) on 31 December 2023. During the last 3 years, it has risen by +$47.56 million (+70.64%). IOVA annual cash & cash equivalents is now -50.42% below its all-time high of $231.73 million, reached on 31 December 2022.IOVA Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$164.19 M
-$64.49 M-28.20%
30 September 2024
Summary:
Iovance Biotherapeutics quarterly cash and cash equivalents is currently $164.19 million, with the most recent change of -$64.49 million (-28.20%) on 30 September 2024. Over the past year, it has dropped by -$103.53 million (-38.67%). IOVA quarterly cash and cash equivalents is now -69.79% below its all-time high of $543.48 million, reached on 31 March 2023.IOVA Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IOVA Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -50.4% | -38.7% |
| 3 y3 years | +70.6% | +180.2% |
| 5 y5 years | +39.9% | +322.2% |
IOVA Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -50.4% | +70.6% | -69.8% | +180.2% |
| 5 y | 5 years | -50.4% | +722.5% | -69.8% | +1075.4% |
| alltime | all time | -50.4% | -69.8% |
Iovance Biotherapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $164.19 M(-28.2%) |
| June 2024 | - | $228.68 M(+70.4%) |
| Mar 2024 | - | $134.19 M(+16.8%) |
| Dec 2023 | $114.89 M(-50.4%) | $114.89 M(-57.1%) |
| Sept 2023 | - | $267.72 M(+16.4%) |
| June 2023 | - | $230.01 M(-57.7%) |
| Mar 2023 | - | $543.48 M(+134.5%) |
| Dec 2022 | $231.73 M(+196.2%) | $231.73 M(+95.8%) |
| Sept 2022 | - | $118.37 M(+9.5%) |
| June 2022 | - | $108.08 M(+17.0%) |
| Mar 2022 | - | $92.36 M(+18.1%) |
| Dec 2021 | $78.23 M(+16.2%) | $78.23 M(+33.5%) |
| Sept 2021 | - | $58.59 M(-29.2%) |
| June 2021 | - | $82.76 M(-37.3%) |
| Mar 2021 | - | $131.95 M(+96.0%) |
| Dec 2020 | $67.33 M(+382.0%) | $67.33 M(-1.4%) |
| Sept 2020 | - | $68.31 M(-57.5%) |
| June 2020 | - | $160.61 M(+205.7%) |
| Mar 2020 | - | $52.54 M(+276.1%) |
| Dec 2019 | $13.97 M(-83.0%) | $13.97 M(-64.1%) |
| Sept 2019 | - | $38.89 M(-49.4%) |
| June 2019 | - | $76.91 M(+42.2%) |
| Mar 2019 | - | $54.09 M(-34.2%) |
| Dec 2018 | $82.15 M(-43.5%) | $82.15 M(+1.8%) |
| Sept 2018 | - | $80.74 M(-67.2%) |
| June 2018 | - | $246.02 M(-17.2%) |
| Mar 2018 | - | $297.08 M(+104.4%) |
| Dec 2017 | $145.37 M(+36.2%) | $145.37 M(-11.0%) |
| Sept 2017 | - | $163.38 M(+43.0%) |
| June 2017 | - | $114.28 M(+6.7%) |
| Mar 2017 | - | $107.10 M(+0.4%) |
| Dec 2016 | $106.72 M | $106.72 M(+14.9%) |
| Sept 2016 | - | $92.89 M(-8.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2016 | - | $101.22 M(+1031.9%) |
| Mar 2016 | - | $8.94 M(-73.4%) |
| Dec 2015 | $33.59 M(-25.2%) | $33.59 M(+229.0%) |
| Sept 2015 | - | $10.21 M(-18.7%) |
| June 2015 | - | $12.56 M(-88.7%) |
| Mar 2015 | - | $111.28 M(+147.8%) |
| Dec 2014 | $44.91 M(+128.3%) | $44.91 M(+161.3%) |
| Sept 2014 | - | $17.19 M(-6.8%) |
| June 2014 | - | $18.44 M(+2.8%) |
| Mar 2014 | - | $17.94 M(-8.8%) |
| Dec 2013 | $19.67 M(>+9900.0%) | $19.67 M(>+9900.0%) |
| Sept 2013 | - | $129.80 K(-77.2%) |
| June 2013 | - | $569.60 K(>+9900.0%) |
| Dec 2012 | $0.00(-100.0%) | $0.00(-100.0%) |
| Sept 2012 | - | $5000.00(-68.2%) |
| June 2012 | - | $15.70 K(>+9900.0%) |
| Mar 2012 | - | $0.00(-100.0%) |
| Dec 2011 | $510.20 K(-60.5%) | $510.20 K(-44.0%) |
| Sept 2011 | - | $910.60 K(+229.8%) |
| June 2011 | - | $276.10 K(-62.2%) |
| Mar 2011 | - | $730.50 K(-43.5%) |
| Dec 2010 | $1.29 M(>+9900.0%) | $1.29 M(+62.4%) |
| Sept 2010 | - | $795.90 K(+280.3%) |
| June 2010 | - | $209.30 K(-32.9%) |
| Mar 2010 | - | $311.80 K(+3611.9%) |
| Dec 2009 | $8400.00(+189.7%) | $8400.00(+1300.0%) |
| Sept 2009 | - | $600.00(-50.0%) |
| June 2009 | - | $1200.00(-25.0%) |
| Mar 2009 | - | $1600.00(-44.8%) |
| Dec 2008 | $2900.00 | $2900.00(-82.7%) |
| Sept 2008 | - | $16.80 K(-5.1%) |
| June 2008 | - | $17.70 K(-45.2%) |
| Mar 2008 | - | $32.30 K |
FAQ
- What is Iovance Biotherapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics annual cash & cash equivalents year-on-year change?
- What is Iovance Biotherapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics quarterly cash and cash equivalents year-on-year change?
What is Iovance Biotherapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of IOVA is $114.89 M
What is the all time high annual cash & cash equivalents for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high annual cash & cash equivalents is $231.73 M
What is Iovance Biotherapeutics annual cash & cash equivalents year-on-year change?
Over the past year, IOVA annual cash & cash equivalents has changed by -$116.84 M (-50.42%)
What is Iovance Biotherapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of IOVA is $164.19 M
What is the all time high quarterly cash and cash equivalents for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high quarterly cash and cash equivalents is $543.48 M
What is Iovance Biotherapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, IOVA quarterly cash and cash equivalents has changed by -$103.53 M (-38.67%)